To investigate the effect of ripasudil hydrochloride hydrate eye drops for retinal vein occlusion(RVO)

To investigate the effect of ripasudil hydrochloride hydrate eye drops for retinal vein occlusion(RVO) - The effect of ripasudil eye drops for RVO

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031064

Enrollment

Registered

2018-02-01

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

Administration of ripasudil eye drops twice a day for 12 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have early glaucoma or ocular hypertension Patients who do not have complete regression of macula edema with intravitreal injection of anti-VEGF drugs, or who need frequent injection of drugs to maintain the condition of complete disappearance of edema Patients aged 20 years and older at the time of informed consent Patients who gave written consent to study participation by free documentation and verbally enough explanation

Exclusion criteria

Exclusion criteria: Patients with other ocular disorders Patients with a bad control of intra ocular pressure Others who are deemed unsuitable for inclusion in the study for any other reason based on the assessment by the investigators

Design outcomes

Primary

Measure	Time frame
The change in central retinal thickness measured by optical coherence tomography before and 12 after the treatment	—

Secondary

Measure	Time frame
The frequency of intravitreal injection of anti-VEGF drugs	—

Countries

Japan

Contacts

Public ContactTsuyoshi Otsuji

Kansai Medical University Medical Center Ophthalmology

otsuji@takii.kmu.ac.jp06-6992-1001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026